Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

Egils Vjaters; Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A

doi:10.1111/bju.12542

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

Egils Vjaters
, Martínez-Piñeiro L
, Schalken JA
, Cabri P
, Maisonobe P
, de la Taille A

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Original language	English
Journal	BJU International
Volume	114
Issue number	4
DOIs	https://doi.org/10.1111/bju.12542
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

OECD Field of Science

3. Medical and Health Sciences

Access to Document

10.1111/bju.12542

Cite this

@article{160c2a96a8c6428f960801a02e4751f9,

title = "Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer",

author = "Egils Vjaters and Mart{\'i}nez-Pi{\~n}eiro L and Schalken JA and Cabri P and \{Maisonobe P\} and \{de la Taille A\}",

year = "2014",

doi = "10.1111/bju.12542",

language = "English",

volume = "114",

journal = "BJU International",

issn = "1464-4096",

publisher = "John Wiley and Sons Inc",

number = "4",

}

Vjaters, E, L, M-P, JA, S, P, C, Maisonobe P & de la Taille A 2014, 'Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer', BJU International, vol. 114, no. 4. https://doi.org/10.1111/bju.12542

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. / Vjaters, Egils; L, Martínez-Piñeiro; JA, Schalken et al.
In: BJU International, Vol. 114, No. 4, 2014.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

AU - Vjaters, Egils

AU - L, Martínez-Piñeiro

AU - JA, Schalken

AU - P, Cabri

AU - Maisonobe P, null

AU - de la Taille A, null

PY - 2014

Y1 - 2014

UR - http://onlinelibrary.wiley.com/doi/10.1111/bju.12542/abstract;jsessionid=51B09257FC8369B95DBA40136ACF2D4B.f04t01%20,%20https://www.ncbi.nlm.nih.gov/pubmed/24806330

U2 - 10.1111/bju.12542

DO - 10.1111/bju.12542

M3 - Article

SN - 1464-4096

VL - 114

JO - BJU International

JF - BJU International

IS - 4

ER -

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

UN SDGs

OECD Field of Science

Access to Document

Other files and links

Cite this